<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–53" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–53/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–53/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_53"><akn:num>379j–53</akn:num><akn:heading>Reauthorization; reporting requirements</akn:heading><akn:content><akn:p>§ 379j–53. Reauthorization; reporting requirements(a) Performance report(1) General requirementsNot later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 401(b) 11 See References in Text note below. of the Biosimilar User Fee Amendments of 2022 during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals. The report for a fiscal year shall include information on all previous cohorts for which the Secretary has not given a complete response on all biosimilar biological product applications and supplements in the cohort.


(2) Additional informationThe report under this subsection shall include the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—(A) information on all previous cohorts for which the Secretary has not given a complete response on all biosimilar biological product applications and supplements in the cohort;

(B) the number of original biosimilar biological product applications filed per fiscal year, and the number of approvals issued by the agency for such applications; and

(C) the number of resubmitted original biosimilar biological product applications filed per fiscal year and the number of approvals 22 So in original. letters issued by the agency for such applications.


(3) Real time reporting(A) In generalNot later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this subpart, the Secretary shall post the data described in subparagraph (B) for such quarter and on a cumulative basis for the fiscal year on the inte</akn:p></akn:content><akn:subsection eId="subsec_379j_53_a"><akn:num>(a)</akn:num><akn:heading>Performance report</akn:heading><akn:content><akn:p>(a) Performance report</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_53_b"><akn:num>(b)</akn:num><akn:heading>Fiscal report</akn:heading><akn:content><akn:p>(b) Fiscal report Not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_53_c"><akn:num>(c)</akn:num><akn:heading>Corrective action report</akn:heading><akn:content><akn:p>(c) Corrective action report For each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit a corrective action report to the Committee on Energy and Commerce and Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and Committee on Appropriations of the Senate. The report shall include the following information, as applicable:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_53_d"><akn:num>(d)</akn:num><akn:heading>Enhanced communication</akn:heading><akn:content><akn:p>(d) Enhanced communication</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_53_e"><akn:num>(e)</akn:num><akn:heading>Public availability</akn:heading><akn:content><akn:p>(e) Public availability The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_53_f"><akn:num>(f)</akn:num><akn:heading>Reauthorization</akn:heading><akn:content><akn:p>(f) Reauthorization</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>